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The X gene product of the human hepatitis B virus
(HBx) is a transcriptional activator of various viral
and cellular genes. We recently have determined that
the production of tumor necrosis factor-a (TNF-a)
by HBV-infected hepatocytes is transcriptionally up-
regulated by HBx, involving nuclear factor of activated
T cells (NF-AT)-dependent activation of the TNF-a
gene promoter. Here we show that HBx activates NF-
AT by a cyclosporin A-sensitive mechanism involving
dephosphorylation and nuclear translocation of the
transcription factor. Luciferase gene expression assays
demonstrated that HBx transactivates transcription
through NF-AT-binding sites and activates a Gal4–NF-
AT chimeric protein. DNA–protein interaction assays
revealed that HBx induces the formation of NF-AT-
containing DNA-binding complexes. Immunofluores-
cence analysis demonstrated that HBx induces the
nuclear translocation of NF-AT, which can be blocked
by the immunosuppressive drug cyclosporin A. Fur-
thermore, immunoblot analysis showed that the HBx-
induced activation and translocation of NF-AT are
associated with its dephosphorylation. Thus, HBx may
play a relevant role in the intrahepatic inflammatory
processes by inducing locally the expression of cyto-
kines that are regulated by NF-AT.
Keywords: cyclosporin A/HBx/hepatitis B virus/NF-AT/
transcription
Introduction
The hepatitis B virus (HBV) is a hepatotrophic virus
composed of a partially double-stranded circular DNA
genome that causes acute and chronic hepatic injury.
Persistent HBV infection is strongly associated with the
development of hepatocellular carcinoma (Ganem and
Varmus, 1987). Four genes, S/preS, C/preC, P and X, are
encoded by the viral genome (Tiollais et al., 1985). The
X gene encodes a 17 kDa protein, termed HBx, that has
been shown to function as a transcriptional transactivator of
a variety of viral and cellular promoter/enhancer elements
(reviewed in Yen, 1996).
HBx does not bind directly to DNA, but it is able
to transactivate transcription through multiple cis-acting
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elements including AP-1, AP-2, ATF/CREB, NF-κB,
C/EBP and Egr-1-binding sites (Maguire et al., 1991;
Kekule´ et al., 1993; Yoo et al., 1996). However, the exact
mechanism of transactivation still remains unresolved. It
has been determined that HBx interacts in the nucleus
with components of the basal transcription machinery,
including RPB5, a subunit of all three mammalian RNA
polymerases, and several transcription factors (Maguire
et al., 1991; Cheong et al., 1995; Qadri et al., 1995; Haviv
et al., 1996, 1998; Lin et al., 1997). Thus, HBx may exert
its effect by mimicking the cellular coactivator function
(Haviv et al., 1996). Another proposed mechanism for
HBx activity involves the activation of signal transduction
pathways such as the Ras/Raf/ERK and MEKK-1/JNK
cascades, leading to induction of AP-1, NF-κB and prob-
ably other transcription factors (Benn and Schneider, 1994;
Natoli et al., 1994b; Doria et al., 1995; Benn et al., 1996;
Su and Schneider, 1996; Klein and Schneider, 1997).
Whether protein kinase C (PKC) is involved in the signal
transduction pathways activated by HBx is less clear
(Cross et al., 1993; Kekule´ et al., 1993; Benn and
Schneider, 1994; Murakami et al., 1994; Natoli et al.,
1994a; Chirillo et al., 1996). HBx has been found to be
distributed in the cytoplasm, but also to some extent in
the nucleus of transfected cells (Doria et al., 1995; Haviv
et al., 1998). Thus, HBx may have a dual function, one
related to its cytoplasmic localization, that can mediate
the activation of signal transduction pathways, and another
nuclear, that may account for the interaction with transcrip-
tion factors and components of the transcription apparatus
to enhance the binding or activity of these proteins (Doria
et al., 1995).
Although there is emerging evidence of the involvement
of HBx in hepatocarcinogenesis (Koike, 1995), very little
is known about the role that this viral protein plays in the
intrahepatic inflammatory processes. In this context, we
previously have reported the production of the pro-
inflammatory cytokine tumor necrosis factor-α (TNF-α)
by hepatocytes from patients chronically infected by HBV.
We also demonstrated that transient or stable transfection
of the hepatoma cell line HepG2 with either the whole
HBV genome or HBx expression vectors resulted in
TNF-α production (Gonza´lez-Amaro et al., 1994). In
addition, it has been reported that the gene encoding
human interleukin 8 (IL-8) is also transactivated by HBx
(Mahe´ et al., 1991). We have shown recently that HBx-
induced TNF-α production by hepatocytes is regulated at
the transcriptional level involving the activation of nuclear
factor of activated T cells (NF-AT) (Lara-Pezzi et al.,
1998).
The expression of TNF-α, IL-8 and other cytokine-
encoding genes is regulated in a co-ordinate manner by
the transcription factor NF-AT in cells of the immune
system (Okamoto et al., 1994; Tsai et al., 1996; Rao et al.,
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1997). Therefore, NF-AT is required for initiating and
controlling effective immune and inflammatory responses.
NF-AT is a family of transcription factors that includes at
least four structurally related proteins; NF-AT1 (previously
named NF-ATp), NF-ATc, NF-AT3 and NF-AT4. Multiple
isoforms and species-specific variants of these proteins
have also been identified. Although NF-AT proteins are
not expressed exclusively by cells of the immune system
(reviewed in Rao et al., 1997), little information is
available regarding the expression and function of NF-AT-
related proteins outside the immune system (Rao, 1994;
Rao et al., 1997).
The activity of NF-AT proteins is tightly regulated by
the calcium/calmodulin-dependent phosphatase calci-
neurin (Sigal and Dumont, 1992; Jain et al., 1993; Crabtree
and Clipstone, 1994; Cantrell, 1996; Loh et al., 1996), a
primary target for inhibition by the immunosuppressive
drugs cyclosporin A (CsA) and FK506 (Schreiber and
Crabtree, 1992; Shaw et al., 1995). Calcineurin controls
the translocation of NF-AT proteins from the cytoplasm
to the nucleus of activated cells by interacting with an
N-terminal regulatory domain conserved in all the mem-
bers of the NF-AT family (Luo et al., 1996b). NF-AT
proteins are able to bind cooperatively with transcription
factors of the AP-1 family to form composite NF-AT:AP-
1 sites (Jain et al., 1993), which are found in the regulatory
elements of many genes that are transcribed inducibly by
cells of the immune system (Boise et al., 1993; Cockeril
et al., 1995; Jain et al., 1995; Rooney et al., 1995).
In this report, we demonstrate that HBx transactivates
transcription through NF-AT-binding sites in liver-derived
Chang (CHL) cells, and that a chimeric Gal4–NF-AT
protein, containing the N-terminal transactivation domain
of NF-AT1 fused to the Gal4 DNA-binding domain (DBD)
is activated by HBx. We also show that HBx induces, in
CHL cells, NF-AT-containing protein complexes that bind
independently of AP-1 to an NF-AT site of the murine
IL-4 promoter. Furthermore, we demonstrate that HBx
triggers dephosphorylation and nuclear translocation of
NF-AT by a CsA-sensitive mechanism.
Results
Transactivation of NF-AT-dependent transcription
by HBx
To analyze whether HBx was able to transactivate trans-
cription through NF-AT-binding sites, CHL cells were
transiently co-transfected with the HBx expression vector
pSV-X along with a luciferase reporter plasmid driven by
three tandem copies of the distal NF-AT site of the IL-2
enhancer (pNF-AT-Luc), which has been reported to bind
NF-AT cooperatively with transcription factors of the
AP-1 family (Boise et al., 1993; Northrop et al., 1993;
Jain et al., 1995). As shown in Figure 1A, the expression
of HBx induced the NF-AT-dependent transcription 4- to
6-fold. Moreover, in the presence of either the mitogen
phorbol 12-myristate 13-acetate (PMA) or the calcium
ionophore A23187, HBx further induced (11- to 14-fold)
NF-AT transcriptional activity, leading to luciferase
expression levels similar to those obtained by co-stimula-
tion with PMA plus the calcium ionophore, which provides
a full stimulus for NF-AT-dependent transcription (Rao
et al., 1997). In contrast, PMA or calcium ionophore alone
7067
exerted a weak effect on the induction of the transcriptional
activity of the NF-AT enhancer, thus suggesting that HBx
may compensate both the mitogenic signals induced by
PMA and the calcium signals induced by calcium iono-
phore in the activation of NF-AT sites. Strikingly, HBx
further increased the induction of the NF-AT enhancer
by co-stimulation with PMA plus calcium ionophore
(Figure 1B). A dominant-negative version of NF-AT,
which lacks the DNA-binding domain and the C-terminal
transactivation domain (Northrop et al., 1994), was able
to prevent the induction by HBx, either alone or in the
presence of PMA and/or calcium ionophore (Figure 1A
and 1B). In addition, CsA, a pharmacological inhibitor of
the phosphatase calcineurin that controls NF-AT activation,
also blocked the induction by HBx as well as the synergistic
induction by HBx and PMA plus calcium ionophore
(Figure 1C), suggesting that activation of NF-AT proteins
was mediating the induction of the NF-AT enhancer
element by HBx.
The synergism of HBx and PMA plus the calcium
ionophore was not due merely to an increase in HBx
expression levels, since these agents did not induce signi-
ficantly the activity of the promoter/enhancer elements
driving the expression of HBx within the plasmid pSV-X
(data not shown). Therefore, distinct mechanisms might
be mediating the synergistic activation of the NF-AT-
dependent transcription by HBx. One such mechanism
could be a further increase by HBx of the PMA-induced
transcriptional activity of AP-1, which binds cooperatively
with NF-AT to the NF-AT enhancer element. To address
this issue, CHL cells were co-transfected with pSV-X
vector and the reporter plasmid pAP-1-Luc, containing
four AP-1-binding sites, and the transfected cells were
either left untreated or stimulated with PMA or PMA plus
calcium ionophore. As shown in Figure 1D, HBx further
activated the AP-1-dependent transcription induced by
PMA (not shown) and by PMA plus calcium ionophore.
However, the activation of AP-1 transcriptional activity
by HBx, either alone or in the presence of PMA or
PMA plus calcium ionophore, was not blocked by CsA
(Figure 1D, and data not shown). Thus, the synergistic
induction of the NF-AT enhancer element by HBx and
PMA plus calcium ionophore may be due, at least in part,
to a stronger activation of the AP-1 component of this
composite NF-AT:AP-1 site.
To substantiate further that HBx was able to induce
transcription through the NF-AT enhancer element via
activation of NF-AT proteins, CHL cells were co-
transfected with a cDNA encoding full-length NF-ATc
along with the pNF-AT-Luc reporter plasmid, either in
the presence or the absence of HBx. Although NF-ATc
had a weak effect on the luciferase activity, probably
due to its cytoplasmic localization after transfection,
when co-transfected with HBx it potently enhanced NF-
AT-Luc expression in a dose-dependent manner (Figure
2A). In addition, the HBx-mediated induction in the
presence of NF-ATc was blocked by the dominant-
negative mutant of NF-ATc (Figure 2A). Similar
functional results were obtained using clones of CHL
cells stably transfected with HBx (CMX), in which NF-
ATc enhanced HBx-mediated induction of the NF-AT
element .6-fold (Figure 2B).
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Fig. 1. HBx transactivates a multimeric NF-AT-containing plasmid. (A) CHL cells were co-transfected with 0.2 µg of the reporter plasmid pNF-AT-
Luc along with 5 µg of either pSV-X or the control plasmid pSV-hygro. Transfected cells were either left untreated or stimulated with PMA or
calcium ionophore (Io). Treatment with PMA plus calcium ionophore was used as control for full stimulus of NF-AT-dependent transcription.
(B) HBx synergizes with PMA plus calcium ionophore in the activation of the NF-AT enhancer element. CHL cells were co-transfected as described
above, and either left untreated or stimulated with PMA and calcium ionophore (PMA 1 Io). To demonstrate the specificity of the activation of the
reporter gene expression, 2 µg of the plasmid pSH102C∆418, which encodes a dominant-negative mutant of NF-AT, were included in the
transfection experiments. (C) Cyclosporin A blocks the activation of the NF-AT enhancer element by HBx. CHL cells were co-transfected as
described above and, where indicated, treated with CsA (200 ng/ml) and/or PMA plus calcium ionophore. (D) HBx synergizes with PMA plus
calcium ionophore in the activation of a multimeric AP-1-containing plasmid in a CsA-independent manner. CHL cells were co-transfected with
0.2 µg of the reporter plasmid pAP-1-Luc along with 5 µg of pSV-X or pSV-hygro. Cells were either left untreated or treated with CsA and/or PMA
plus calcium ionophore. The luciferase activities are represented as fold induction over the expression of pNF-AT-Luc or pAP-1-Luc in the absence
of any stimuli. The values shown in (A), (B) and (C) represent the mean fold-induction (6SD) of at least three independent experiments. The values
shown in (D) are representative of three experiments.
HBx targets the transactivation domain of NF-AT
To confirm the role of NF-AT proteins in HBx-mediated
transcriptional activation of the NF-AT enhancer element,
a Gal4-derived reporter system was employed, which in
mammalian cells responds only to artificial activators. To
carry out these studies, the chimeric vector, pGal4-NF-
AT1(1–415), encoding the Gal4 DBD fused to the trans-
activation domain of NF-AT1, or the parental vector
pRSV-Gal4-DBD (Luo et al., 1996a) were co-transfected
into CHL cells along with the luciferase reporter plasmid
pGal4-Luc, either in the presence or the absence of the
HBx expression vector pSV-X. As expected, HBx did
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not stimulate transcription when co-transfected with the
control plasmid encoding the Gal4 DBD (Figure 3A).
However, transcription of the pGal4-Luc reporter plasmid
was induced up to 16-fold by HBx when co-transfected
with Gal4–NF-AT1 expression vector (Figure 3A). Sim-
ilarly, in CMX cells, HBx induced Gal4-Luc expression
~18-fold, when compared with control CMO cells, using
three different amounts of Gal4–NF-AT1 expression vector
(Figure 3B). Taken together, these results strongly indicate
that HBx is able to activate NF-AT either by direct
protein–protein interaction or by mimicking the signals
involved in the activation of these proteins.
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Fig. 2. HBx synergizes with transfected full-length NF-ATc-encoding
cDNA. (A) CHL cells were co-transfected with 0.2 µg of pNF-AT-
Luc, 5 µg of pSV-X or pSV-hygro, and increasing amounts of pNF-
ATcwt. To keep the amount of plasmid DNA in each transfection point
constant, the empty vector pBJ5 and 5 µg of the carrier plasmid
pGEM7 were used. (B) Empty vector cells (CMO) and HBx
expression cells (CMX) cells were co-transfected with 0.2 µg of pNF-
AT-Luc, 0.2 µg of the expression plasmid pNF-ATcwt or the empty
vector pBJ5. The dominant-negative NF-AT-encoding plasmid
pSH102C∆418 (2 µg) was included in the transfection experiments to
demonstrate the specificity of the activation. The luciferase activities
are represented as fold induction over the expression of pNF-AT-Luc
in the absence of any stimuli. Results shown are representative of four
experiments. Three different clones of CMO and CMX cells were
employed in the experiments.
HBx induces NF-AT DNA-binding activity
To examine whether HBx was able to induce the formation
of NF-AT-containing DNA–protein complexes, electro-
phoretic mobility shift assays (EMSAs) were performed
using a 32P-labeled oligonucleotide that contained the
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Fig. 3. HBx activates a Gal4–NF-AT1 chimeric protein containing the
transactivation domain of NF-AT1. (A) CHL cells were co-transfected
with 1 µg of the reporter plasmid pGal4-Luc along with 5 µg of either
the expression vector encoding the fusion protein Gal4–NF-AT1
(1–415) or the parental empty vector pRSV-Gal4-DBD, and increasing
amounts of pSV-X. To keep the total amount of DNA constant,
pSV-hygro was used. (B) CMO and CMX cells were co-transfected
with 1 µg of pGal4-Luc and increasing amounts of the expression
vector pGal4-NF-AT1(1–415). To keep the amount of DNA constant,
the parental vector pRSV-Gal4-DBD was used. The luciferase
activities are represented as fold-induction over the values obtained in
CHL cells or CMO cells co-transfected with pGal4-Luc and pRSV-
Gal4-DBD, and are representative of three independent experiments.
The results obtained with the stable transfectants were verified by
using different clones of CMO and CMX cells.
NF-AT-binding site of the mouse IL-4 promoter, which
can bind NF-AT independently of AP-1 (Rooney et al.,
1994, 1995), and nuclear extracts from CHL cells stably
transfected with either CMX or CMO. Three major specific
complexes were resolved using nuclear extracts from
HBx-expressing cells that were not detectable in CMO
control cells (Figure 4A). These inducible complexes
resulted from specific DNA binding since their formation
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Fig. 4. HBx induces the formation of NF-AT-containing DNA-binding
complexes. (A) A 2 µg aliquot of protein from CMO or CMX nuclear
extracts was incubated with a 32P-labeled probe containing the NF-AT-
binding site of the murine IL-4 promoter. For competition, a 130-fold
molar excess of the homologous NF-AT oligonucleotide or an
oligonucleotide containing an SP-1-binding site were used. The three
specific complexes formed in the presence of HBx are indicated.
(B) CMO and CMX cells were stimulated with PMA (10 ng/ml) plus
calcium ionophore (1 µM) for 16 h and the complexes formed
compared with those obtained in the absence of stimuli. (C) The
HBx-induced complexes are competed by the homologous NF-AT
oligonucleotide (40-fold excess) but not by a mutated NF-AT
oligonucleotide (40- and 130-fold) or an AP-1 oligonucleotide
(130-fold excess). (D) Prior to adding the IL-4-NF-AT probe, 0.5 µl of
either pre-immune antiserum (P. I.) or antibodies against different
members of the NF-κB, NF-AT or AP-1 families were included in the
binding reaction. Supershifted bands induced by the anti-NF-ATc
monoclonal antibody and by the anti-NF-AT1 antiserum (672) are
indicated by arrows.
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was blocked by an excess of unlabeled IL4-NFAT oligo-
nucleotide, but not by an unrelated oligonucleotide con-
taining an SP-1-binding site. Three DNA–protein
complexes, with electrophoretic mobility identical to those
induced by HBx, were resolved using nuclear extracts
from CMO cells treated with PMA plus calcium ionophore,
which were used as a positive control for NF-AT activation
(Figure 4B). It is noteworthy that PMA plus calcium
ionophore treatment was a stronger stimulus than HBx
for the formation of these complexes. In addition, HBx
expression did not appear to enhance further the binding
activity of these proteins induced by PMA plus calcium
ionophore (Figure 4B). To characterize these HBx-induced
complexes, an IL4-NFAT oligonucleotide bearing
mutations in the core NF-AT-binding site was included in
the competition assays. As shown in Figure 4C, two
different amounts of the mutated IL4-NFAT oligonucleo-
tide had no detectable effect on the generation of the
inducible complexes, whereas similar amounts of the wild-
type oligonucleotide completely abolished their formation.
As an additional control, an oligonucleotide including an
AP-1 consensus site failed to compete the specific bands
generated with the NF-AT probe, suggesting that these
complexes contained NF-AT-related proteins that bind to
the oligonucleotide independently of the Fos/Jun family
proteins.
To identify further the IL4-NFAT-binding factors
induced by HBx, specific antibodies for NF-κB, NF-AT
and Fos/Jun proteins were added to the binding reactions.
As shown in Figure 4D, neither a pre-immune antiserum
nor antisera against the NF-κB family members p50,
Rel A and p52 (not shown) affected any of the DNA–
protein complexes. In contrast, addition of a monoclonal
antibody specific for NF-ATc prevented the formation of
complex 1 and generated a supershifted band. An anti-
serum against NF-AT, which recognizes NF-AT1 and
probably other members of the family (see Materials and
methods), reduced complex 2 and prevented the formation
of complex 3. On the other hand, an antiserum specific
for NF-AT1 (672) significantly reduced complex 3, abol-
ished the formation of complex 2 and generated a super-
shifted band. Taken together, these results suggest that
complex 1 is composed mainly by NF-ATc, and that
complexes 2 and 3 contain NF-AT1. These results also
indicate that the inducible bands do not contain detectable
amounts of NF-κB-related proteins, in agreement with
previous observations which demonstrated that NF-κB
family members bind with very low affinity to the
NF-AT site of the mouse IL-4 promoter (Casolaro et al.,
1995). Consistent with the competition assays, the HBx-
induced complexes were not affected by antibodies recog-
nizing various members of the Fos and Jun families.
HBx triggers nuclear translocation and
dephosphorylation of NF-AT
To investigate whether the activation of NF-AT-dependent
transcription and NF-AT binding by HBx involved the
nuclear translocation of NF-AT proteins, the cellular
distribution of a transiently expressed HA-tagged NF-ATc
protein (Northrop et al., 1994) was analyzed by indirect
immunofluorescence staining in clones of CHL cells either
expressing or not expressing HBx. As summarized in
Table I, ~40% of the stable CMX cells displayed a nuclear
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Table I. NF-AT is translocated to the nucleus in CMX but not in
CMO cells
Cell Treatment % Nuclear translocationa nb
CMO – 8.6 122
CMO/Dex – 4.1 73
CMO P 1 Io 90.1 91
CMO/Dex P 1 Io 100 90
CMX – 40.7 73
CMX/Dex – 75.2 86
CMX/Dex CsA 15.7 60
CMX P 1 Io 90.6 85
CMX P 1 Io/CsA 10.2 53
CMX/Dex P 1 Io 100 52
CMX/Dex P 1 Io/CsA 29.6 72
CMO and CMX cells were transfected with the HA-tagged NF-AT
mutant vector pSH102C∆418 and were stimulated or not with 1 µM
dexamethasone for 16 h. Where indicated, cells were treated with
200 ng/ml CsA (2 h) or 10 ng/ml PMA plus 1 µM calcium
ionophore (30 min). Cells were analyzed by immunofluorescence
with an anti-HA antibody.
aPercentage of cells displaying total or partial nuclear translocation
of HA-NF-AT are shown.
bNumber of transfected cells analyzed at each transfection point.
pattern of staining of HA-NF-AT. Treatment of CMX cells
with dexamethasone, which augmented the level of HBx
expression (see Materials and methods), further increased
the number of cells with nuclear HA-NF-AT up to 75%
(Table I; Figure 4). In contrast, in control cells (CMO),
either treated with dexamethasone or untreated, the fusion
protein was found largely in the cytoplasm (Table I; Figure
5). A predominant nuclear localization of HA-NF-AT was
observed in both HBx-expressing and non-expressing cells
stimulated with PMA plus calcium ionophore (Table I;
Figure 5). Thus, the expression of HBx appears to induce
constitutive nuclear translocation of NF-AT proteins in
the absence of conventional calcium-mobilizing stimuli.
Interestingly, the immunosuppressor CsA prevented the
nuclear translocation of NF-AT triggered by both PMA
plus calcium ionophore treatment and HBx expression
(Table I; Figure 5), indicating the involvement of the
phosphatase calcineurin in the translocation of NF-AT
induced by both stimuli. Similarly, transient co-transfec-
tion of CHL cells with the HA-NF-AT expression plasmid
and the HBx expression vector pSV-X resulted in a
predominant nuclear localization of HA-NF-AT, whereas
the cells co-transfected with the control vector pSV-hygro
displayed a cytoplasmic distribution of the fusion protein
(Figure 6). Moreover, treatment of the cells transfected
with the control vector with PMA plus calcium ionophore
also resulted in a nuclear staining pattern of HA-NF-AT.
CsA blocked the nuclear translocation induced by HBx
and by PMA plus calcium ionophore (Figure 6).
We further confirmed the effect of HBx on the transloca-
tion of NF-AT by transient co-transfection experiments in
the T-cell line Jurkat, where the mechanism of NF-AT
activation/translocation previously has been characterized
(Luo et al., 1996b; Martı´nez-Martı´nez et al., 1997). As
shown in Figure 7, co-expression of HBx and HA-NF-AT
resulted in a clear nuclear localization of the fusion
protein, whereas the control cells, transfected with the
empty vector, displayed a cytoplasmic distribution of HA-
NF-AT. A nuclear distribution of HA-NF-AT was also
observed in both HBx-expressing cells and in control
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cells, when they were stimulated with PMA plus calcium
ionophore. As above, CsA prevented the nuclear transloca-
tion triggered by HBx and a mitogenic stimulus (Figure 7).
The activation and translocation of NF-AT proteins by
various calcium-mobilizing stimuli involve the dephos-
phorylation of these proteins, and the dephosphorylated
forms of NF-AT migrate more rapidly than fully phos-
phorylated forms on SDS–PAGE (Martı´nez-Martı´nez
et al., 1997). To examine whether HBx-mediated activation
and translocation of NF-AT also resulted from its
dephosphorylation, immunoblotting studies were per-
formed in CMX and CMO cells transiently transfected
with HA-tagged NF-ATc. The phosphorylation state of
the fusion protein was analyzed by Western blot using an
anti-HA antiserum (Figure 8). In control cells (CMO),
a single HA-NF-AT protein band was detected, which
corresponded to the phosphorylated form, whereas in
CMX cells a significant amount of HA-NF-AT was present
in its rapidly migrating dephosphorylated form. Treatment
with PMA plus calcium ionophore induced the dephos-
phorylation of a large amount of the transfected HA-NF-
AT in both CMX and CMO cells. In agreement with the
translocation studies, CsA prevented the dephosphoryl-
ation induced by HBx and PMA plus calcium ionophore.
Taken together, these results indicate that the activation
of NF-AT by HBx is associated, at least in part, with its
dephosphorylation and translocation, and that it is mediated
by a mechanism involving deregulation of calcineurin.
Discussion
Chronic infection of the liver by HBV leads to profound
changes in hepatocyte physiology including the expression
of various molecules that normally are not expressed, or
expressed at very low levels, by uninfected hepatocytes
(Chisari and Ferrari, 1995). It has been shown that the
expression of many of these molecules is transcriptionally
up-regulated by HBx, the transcriptional transactivator of
HBV (Yen, 1996). In this context, we have demonstrated
that human hepatocytes infected by HBV produce the pro-
inflammatory cytokine TNF-α both in vivo and in vitro
(Gonza´lez-Amaro et al., 1994). In addition, we have
demonstrated that the proximal region of the TNF-α gene
promoter contains target sequences for HBx transactivation
(Lara-Pezzi et al., 1998). The expression of TNF-α is
almost exclusively restricted to cells of hematopoietic
origin (Vassalli, 1992), and is controlled by pre-existing
transcription factors belonging to the NF-κB/Rel and NF-
AT families, which ensure a rapid response to extracellular
stimuli. In cells of the myeloid lineage, the inducible
expression of TNF-α is regulated mainly by members of
the NF-κB/Rel family (Trede et al., 1995; Yao et al.,
1997), whereas in lymphocytes the expression of TNF-α
is tightly controlled by NF-AT proteins (Tsai et al., 1996).
We have shown that the HBx-mediated induction of the
TNF-α gene promoter can be interfered with by a domin-
ant-negative mutant of NF-AT, but not by the cytoplasmic
inhibitor of NF-κB proteins IκBα (Lara-Pezzi et al.,
1998), suggesting that NF-AT proteins may have a role
in the expression of TNF-α by HBV-infected hepatocytes.
We have demonstrated herein that HBx is able to
activate NF-AT by a CsA-sensitive mechanism involving
dephosphorylation and nuclear translocation of this trans-
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Fig. 5. NF-AT is translocated to the nucleus in CMX but not in CMO cells. Different clones of CMO and CMX cells were transfected with the
plasmid pSH102C∆418, encoding the HA-tagged NF-AT deletion mutant, and stimulated with 1 µM dexamethasone for 16 h. Where indicated, the
transfected cells were treated with 200 ng/ml CsA for 2 h and/or 10 ng/ml PMA plus 1 µM calcium ionophore (PMA 1 Io) for 30 min. Cells were
fixed and analyzed for immunofluorescence with an anti-HA antibody. Representative fields where total translocation of NF-AT took place are shown
for CMX cells, either unstimulated or stimulated with PMA 1 Io, and for PMA 1 Io-treated CMO cells.
cription factor. Since the HBx-mediated transactivation
experiments carried out in this study involved measuring
reporter gene expression driven by a composite NF-AT:AP-
1 site of the IL-2 enhancer, their interpretation was
necessarily complex, and it might not be apparent whether
NF-AT proteins or AP-1 proteins were affected. Given
that both PMA and HBx can trigger the signal transduction
pathways leading to activation of AP-1, it was expected
that HBx would substitute effectively for PMA and
synergize with calcium ionophore to stimulate the NF-AT
enhancer element. In contrast, it had not been determined
whether HBx was able to regulate the calcium-dependent
pathways involved in the activation of the transcription
factor NF-AT. In this regard, HBx appears to be able to
substitute effectively for calcium ionophore and synergize
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with PMA to activate the pNF-AT-Luc reporter plasmid.
Therefore, HBx appears to be sufficient to induce the
intracellular signals necessary to activate transcription
through composite NF-AT:AP-1 sites, present in many
regulatory elements of cytokine-encoding genes, as
demonstrated by the fact that HBx alone is able to
transactivate the NF-AT enhancer element of the IL-2 gene.
In this work, we present three lines of evidence indicat-
ing that HBx is able to functionally activate NF-AT: first,
the induction of the reporter plasmid pNF-AT-Luc by
HBx, either alone or in synergy with PMA and/or calcium
ionophore, can be disrupted by a dominant-negative mutant
of NF-AT and by the immunosuppressive drug CsA;
secondly, the transiently transfected NF-ATc protein
potently activates the NF-AT enhancer element only in
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Fig. 6. NF-AT is translocated to the nucleus in CHL cells transiently transfected with the HBx expression vector. CHL cells were co-transfected with
the plasmid pSH102C∆418, encoding the HA-tagged NF-AT deletion mutant, and either the HBx-expressing vector pSV-X or the negative control
pSV-hygro. The cells were either left untreated or treated with 200 ng/ml CsA for 2 h and/or 10 ng/ml PMA plus 1 µM calcium ionophore
(PMA 1 Io) for 30 min. Cells were fixed and analyzed for immunofluorescence with an anti-HA antibody.
the presence of HBx; and thirdly, a chimeric Gal4–NF-
AT protein, containing the transactivation domain of NF-
AT, can mediate transcriptional activation by HBx. These
functional data are supported further by the ability of HBx
to trigger dephosphorylation, nuclear translocation and
DNA-binding activity of NF-AT.
Mechanistically, dephosphorylation of NF-AT by the
calcium/calmodulin-dependent phosphatase calcineurin
appears to be the major activation pathway of NF-AT
proteins in cells of the immune system (Rao et al., 1997).
However, additional calcineurin-independent and CsA-
resistant pathways of NF-AT activation have also been
reported (Ghosh et al., 1996). In this regard, the HBx-
triggered dephosphorylation and nuclear translocation of
NF-AT as well as the HBx-induced transactivation of the
NF-AT enhancer element are sensitive to CsA treatment,
suggesting that the activation of NF-AT by HBx may be
mediated, at least in part, by deregulation of calcineurin.
However, a distinct mechanism that synergizes with the
calcium/calcineurin pathway may also be involved in the
activation of the NF-AT enhancer by HBx, as suggested
by the fact that HBx is able to augment further the
induction of the pNF-AT-Luc plasmid by co-stimulation
with PMA plus calcium ionophore, which has been
described to provide a full stimulus for NF-AT-dependent
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transcription in cells of the immune system (Rao et al.,
1997). Although alternative explanations cannot be ruled
out, our results indicate that the synergistic activation of
the NF-AT enhancer by HBx and PMA plus calcium
ionophore could be mediated, at least to some extent,
through a stronger activation of the AP-1 component of
this composite NF-AT:AP-1 site. It is also likely that HBx
may activate the transcriptional activation domain of
NF-AT, once this transcription factor has targeted its
recognition sequences, by a mechanism involving direct
protein–protein interaction, as has been shown for other
transcription factors (Haviv et al., 1995, 1996; Yoo
et al., 1996).
Recently, it has been shown that the tax gene product
of the human T-cell leukemia virus (HTLV) induces IL-2
gene expression by a CsA-sensitive mechanism involving
dephosphorylation and activation of NF-AT1 (Good et al.,
1996, 1997). Moreover, it has been determined that activa-
tion of NF-ATc by the HIV transactivator Tat plays an
important role on HIV gene expression and replication
(Kinoshita et al., 1997). In contrast to these lymphotrophic
viruses, HBV infects mainly hepatocytes, in which no
information is available regarding the expression and
function of NF-AT-related proteins. For the first time, to
our knowledge, we provide herein evidence of expression
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Fig. 7. HBx triggers nuclear translocation of NF-AT in the T-cell line Jurkat. Jurkat cells were transiently co-transfected with pSV-X (left column) or
pSV-hygro (right column) and the plasmid pSH102C∆418, which encodes the HA-NF-AT mutant. Where indicated, transfected cells were treated for
2 h with CsA and/or PMA plus calcium ionophore for 30 min. The cells were fixed and analyzed for immunofluorescence with an anti-HA antibody.
Fig. 8. HBx induces NF-AT dephosphorylation. CMO and CMX cells
were transfected with 1.5 µg of the HA-tagged NF-AT mutant vector
pSH102C∆418. Cells were treated overnight with 1 µM
dexamethasone and stimulated where indicated with 200 ng/ml CsA or
10 ng/ml PMA plus 1 µM calcium ionophore (PMA 1 Io). Total cell
extracts were analyzed by Western blot using an anti-HA antibody.
Dephosphorylated and phosphorylated forms of HA-NF-AT are
indicated by arrows. The CMX panel displays less HA-NF-AT protein
because, in this particular experiment, CMX cells were transfected less
efficiently with the HA-NF-AT expression vector.
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of NF-AT family members within CHL cells, and that
these NF-AT proteins can be activated by HBx, as demon-
strated by reporter gene and mobility shift assays. Our
findings raise further questions about the expression of
other NF-AT-regulated genes by HBV-infected hepato-
cytes. In this context, it has been determined that HBx
transactivates the human IL-8 gene through a κB-like cis-
acting element (Mahe´ et al., 1991), which recently has
been shown to behave in vivo as a functional NF-AT site
in T cells (Okamoto et al., 1994; Rao et al., 1997). The
expression of other pro-inflammatory cytokines such as
IL-1β, interferon-γ and IL-6 has been described to take
place in the liver during acute and chronic hepatitis B,
but it has not been established yet whether these cytokines
are produced only by non-parenchymal cells or also by
hepatocytes (Fukuda et al., 1995; Shindo et al., 1996).
On the other hand, it is well known that HBV, although
unable to replicate actively, can also infect cells of the
immune system (Ferrari et al., 1992; Franco et al., 1992),
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making it conceivable that HBx, like Tax and Tat, may
also induce the expression of cytokine-encoding genes in
these cells.
The liver may function as an important source of
cytokine production and participates in the systemic
defence mechanisms that take place after injury or infection
(Andus et al., 1991). It is likely that the infection of
hepatocytes by HBV may initiate the cytokine cascade
that mediates the host immune response and inflammatory
process by inducing locally the expression of several
cytokines that are up-regulated by NF-AT and other HBx-
inducible transcription factors. The underlying abnormality
in chronic hepatitis B is an alteration of the cell-mediated
immune response, which remains strong enough to cause
hepatocellular necrosis but insufficient to clear the virus
(Chisari and Ferrari, 1995). It recently has been reported
that prolonged exposure of T lymphocytes to TNF-α, a
cytokine that is highly produced in HBV-infected patients,
suppresses T-cell function by attenuating T-cell receptor
signaling (Cope et al., 1997), suggesting that this might
be a mechanism of viral persistence. Chronic liver injury
and the inflammatory and regenerative responses create
the stimuli for DNA damage that may lead to the develop-
ment of hepatocellular carcinoma. Elucidation of the
molecular basis for the HBV-triggered cytokine network
may yield therapeutic strategies to terminate chronic HBV
infection and reduce the risk of its sequellae.
Materials and methods
Plasmid constructs
The expression vectors pSV-X and pSV-hygro, harboring the HBx open
reading frame (ORF) and the bacterial hygromycin phosphotransferase
gene, respectively, under the control of the SV40 early promoter/enhancer
have been described elsewhere (Chirillo et al., 1996). The expression
vectors pMMTV-X and pMMTV-CAT, containing the HBx ORF and the
bacterial chloramphenicol acetyltransferase (CAT) gene under the control
of the glucocorticoid-inducible promoter/enhancer of the mouse mam-
mary tumor virus (MMTV), were a gift of Dr M.Levrero (Rome, Italy)
(Chirillo et al., 1997). The plasmids pNFATcwt and pSH102C∆418 (a
kind gift of Dr G.Crabtree, Stanford, CA) are derivatives of pBJ5 vector
and encode, respectively, the full-length protein NF-ATc cDNA and an
NF-ATc deletion mutant (1–418), fused to an N-terminal HA tag, which
functions as a dominant-negative mutant for all the NF-AT isoforms.
pSH102C∆418 lacks the DNA-binding domain and the C-terminal
transactivation domain, but maintains its ability to interact with cal-
cineurin through the NF-AT homology region (Northrop et al., 1994).
The reporter construct pNFAT-Luc contains three tandem copies of the
distal NF-AT-binding site of the human IL-2 enhancer fused to the
minimal IL-2 promoter and was provided by Dr G.Crabtree (Durand
et al., 1988). The plasmid pAP1-Luc that contains the minimal rat
prolactin promoter and four copies of the human collagenase TRE site
(Lara-Pezzi et al., 1998) was a gift of Dr R.A.Flavell (Howard Hughes
Medical Institute, Yale University, New Haven, CT). The pGal4-Luc
reporter plasmid, which carries five copies of the Gal4-binding sequence
fused to the luciferase gene (kindly provided by Dr R.Perona), has been
described previously (Minden et al., 1995). The plasmids pGal4-
NFAT1(1–415) encoding the transactivation domain of NF-AT1 (amino
acids 1–415) in-frame with the Gal4 DBD, and pRSV-Gal4-DBD, which
includes only the DBD (amino acids 1–147), were a gift of Dr A.Rao
(Boston, MA) (Luo et al., 1996a).
Cell culture and reagents
CHL cells (ATCC CCL13) were grown at 37°C with a 5% CO2
atmosphere in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and
50 µg/ml gentamycin. CMO and CMX clones were generated by stably
transfecting CHL cells with the plasmids pMMTV-CAT and pMMTV-X,
respectively, which drive the expression of CAT or HBx in a glucocorti-
coid-inducible manner (Chirillo et al., 1997). Clones were selected in the
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presence of 0.2 mg/ml hygromycin (Boehringer Mannheim, Mannheim,
Germany), and the inducible expression of HBx was analyzed by PCR
and Northern blot. In order to confirm the results obtained with these
transfectants, different clones of CMO and CMX cells were used in
each experiment. The T-cell line Jurkat was grown in RPMI 1641 (Life
Technologies LTI, Paisley, Scotland), supplemented with 10% FCS,
2 mM L-glutamine and 50 µg/ml gentamycin. Where indicated, CMO
and CMX cells were treated with 1 µM of the water analog of
dexamethasone D-2915 (Sigma, St Louis, MO). PMA and the calcium
ionophore A23187 were obtained from Sigma. CsA was purchased from
Sandoz Pharmaceuticals Co. (East Hanover, NJ).
Transfections and luciferase assays
CHL cells, at 50–70% confluence, were co-transfected with 0.2 µg of
the reporter plasmids pNFAT-Luc or pAP-1-Luc, along with 5 µg of
pSV-X, or the negative control pSV-hygro, using the DOSPER reagent
(Boehringer Mannheim), according to the manufacturer’s instructions.
Where indicated, 2 µg of the dominant-negative NF-AT expression
vector pSH102C∆418 or varying amounts of the full-length NF-ATc
expression vector pNF-ATcwt were added. The empty vector pBJ5 was
used to keep the total amount of DNA constant. The transfected cells
were either left untreated or stimulated with PMA (10 ng/ml) and/or
calcium ionophore (1 µM) for 16 h prior to harvesting. Where indicated,
cells were treated with CsA (200 ng/ml) for 40 h. CMO and CMX cells
were co-transfected with 0.2 µg of pNF-AT-Luc, 0.2 µg of pNF-ATcwt
or pBJ5 and 5 µg of the carrier plasmid pGEM-7 (Promega, Madison,
WI). Where indicated, 2 µg of pSH102C∆418 were included. For Gal4-
dependent transactivation experiments, 1 µg of the pGal4-Luc reporter
construct, 5 µg of pRSV-Gal4-DBD or pGal4-NFAT1(1–415) and increas-
ing amounts of pSV-X were transfected into CHL cells using the
DOSPER reagent. CMO and CMX cells were transfected with 1 µg of
reporter plasmid pGal4-Luc and increasing amounts of the pGal4-NF-
AT1(1–415) vector. In order to induce the expression of HBx, 1 µM
dexamethasone was added to transfected CMO and CMX cells 16 h
prior to harvest. The results obtained with the stable transfectants were
confirmed using different clones of CMO and CMX cells. Luciferase
activity was measured in a Lumat LB9501 luminometer (Berthold,
Wildbad, Germany), and normalized to transfection efficiency, which
was determined by co-transfecting 0.5 µg of pRL-null and measuring
Renilla luciferase activity using the Dual-Luciferase Reporter Assay
System (Promega).
Electrophoretic mobility band shift assays
Small-scale nuclear extracts were prepared from CMO and CMX cells
at 30–70% confluence either untreated or stimulated with PMA
(10 ng/ml) plus calcium ionophore (1 µM) as previously described
(Schreiber et al., 1989). Binding reactions were performed at 4°C in a
volume of 18.5 µl containing 10 mM HEPES pH 7.6, 10% glycerol,
50 mM KCl, 6 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 2.5 µg
of poly(dI–dC), 0.75–1 ng of 39-end-labeled probe and 2 µg of nuclear
extracts. For competition, a 40- or 130-fold excess of unlabeled oligonu-
cleotide was added to the reaction prior to the addition of the probe.
The DNA–protein complexes were resolved by electrophoresis on 4%
polyacrylamide gels. The nucleotide sequences of the oligonucleotides
(and their complementaries) used are: 59-gatcATAAAATTTT-
CCAATGTAAA-39 (NF-AT-binding site of the murine IL-4 promoter),
59-gatcATAAAATTTaggtATGTAAA-39 (mutated NF-AT-binding site of
the murine IL-4 promoter), 59-gatcATTCGATCGGGGCGGGGCGAG-
39 (SP-1 consensus binding site) and 59-gatcCGCTTGATGAGTCA-
GCCGGAA-39 (AP-1-binding site).
For supershift assays, 0.5 µl of antibody was added 10 min prior to
the labeled probe, using the following antibodies: anti-NFAT1 antiserum
(Upstate Biotechnology, Lake Placid, NY), which recognizes NF-AT1
but its cross-reactivity with other NF-AT family members has not been
tested; anti-NFAT1 antiserum 672, which was raised against the synthetic
peptide NH2-CSPPSGPAYPDDVLDYGLK (residues 53–70 of human
NF-AT1) as previously described (Lyakh et al., 1997); anti-NFATc
monoclonal antibody (Alexis Corporation, San Diego, CA); anti-Jun and
anti-Fos family antisera (Santa Cruz Biotechnology, Santa Cruz, CA);
and anti-RelA and anti-p50 antisera (provided by Dr E.Mun˜oz, Co´rdoba,
Spain) (Kieran et al., 1990).
Immunofluorescence analysis
CMO and CMX cells were transfected with 1.5 µg of pSH102C∆418,
which expresses an HA-tagged NF-ATc mutant, and 8.5 µg of an
irrelevant plasmid using the DOSPER reagent. At 24 h after transfection,
cells were plated on coverslips and were grown overnight in the presence
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or absence of 1 µM dexamethasone. Where indicated, cells were treated
for 2 h with CsA (200 ng/ml) and/or PMA (10 ng/ml) plus calcium
ionophore (1 µM) for 30 min. The subcellular localization of NF-AT
was analyzed by immunofluorescence with an anti-HA antibody (12CA5).
The percentages of cells displaying total or partial nuclear translocation
of HA-NF-AT were visually scored after counting at least 50 HA-
expressing cells. The statistical analysis was performed using different
clones of CMO and CMX cells.
CHL cells were co-transfected with 0.5 µg of pSH102C∆418 and
1.5 µg of either pSV-X or the control plasmid pSV-hygro, using the
FuGENE-6 liposomal reagent, following the manufacturer’s instructions.
Where indicated, cells were treated with CsA (200 ng/ml) for 2 h and/
or with PMA (10 ng/ml) plus calcium ionophore (1 µM) for 30 min.
The subcellular localizaton of HA-NF-AT was analyzed by immuno-
fluorescence with the anti-HA antibody 12CA5.
Jurkat cells (107) were transiently co-transfected with 1.5 µg of
pSH102C∆418 and 3.5 µg of pSV-X, or the control plasmid pSV-hygro,
using the Lipofectin reagent (Life Technologies), according to the
manufacturer’s recommendations. At 48 h after transfection, cells were
plated on polylysine-coated coverslips and were either left untreated or
treated with CsA (200 ng/ml) for 2 h and/or PMA (10 ng/ml) plus
calcium ionophore (1 µM) for 30 min. HA-NF-AT localization was
analyzed by immunofluorescence with the anti-HA antibody 12CA5.
Western blots
CMO and CMX cells were transfected with 1.5 µg of pSH102C∆418
and 8.5 µg of an irrelevant plasmid, and 24 h later were stimulated
overnight with 1 µM dexamethasone and, where indicated, cells were
treated for 2 h with CsA (200ng/ml) and/or PMA (10 ng/ml) plus
calcium ionophore (1 µM) for 30 min. After washing twice with ice-
cold phosphate-buffered saline (PBS), cells were lysed on the plate with
100 µl of Laemmli buffer, boiled for 5 min and separated by electro-
phoresis in SDS–8% polyacrylamide gels under reducing conditions.
Proteins were transferred onto nitrocellulose membranes (Bio-Rad,
Hercules, CA) that were incubated in blocking solution [5% skimmed
milk in Tris-buffered saline (TBS) buffer] overnight at 4°C, washed
three times in TBS-T (0.1% Tween-20 in TBS) and incubated with the
anti-HA antibody (12CA5) supernatant (diluted 1:5 in TBS-T) for 2 h
at room temperature. Membranes were washed three times in TBS-T
and incubated with a peroxidase-labeled rabbit anti-mouse IgG (DAKO,
Glostrup, Denmark), 1:3000 in TBS-T, for 2 h at room temperature.
After three washes in TBS-T and one wash in H2O, membrane-bound
antibody was visualized with the enhanced chemiluminescence (ECL)
detection reagent (Amersham, Little Chalfont, UK).
Acknowledgements
We are very grateful to Drs A.Rao, G.Crabtree, M.Levrero, A.Flavell
and E.Mun˜oz for providing us with critical reagents that have made this
work possible. This work was supported by grants PM 96-0017 (to
M.L.C.) and PM 96-0076 (to J.M.R.) from Ministerio de Educacio´n y
Ciencia of Spain; a shared grant, AC/07/046/96, from Comunidad
Auto´noma de Madrid to M.L.C. and J.M.R. E.L.P. was supported by a
fellowship from Comunidad Auto´noma de Madrid; and A.L.A. was
supported by grant 07/046/96 from Comunidad Auto´noma de Madrid.
References
Andus,T., Bauer,J. and Gerok,W. (1991) Effects of cytokines on the
liver. Hepatology, 13, 364–375.
Benn,J. and Schneider,R.J. (1994) Hepatitis virus HBx protein activates
Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase
signalling cascade. Proc. Natl Acad. Sci. USA, 91, 10350–10354.
Benn,J., Su,F., Doria,M. and Schneider,R.J. (1996) Hepatitis B virus
HBx protein induces transcription factor AP-1 by activation of
extracellular signal-regulated and c-jun N-terminal mitogen-activated
protein kinases. J. Virol., 70, 4978–4985.
Boise,L.H. et al. (1993) The NFAT-1 DNA binding complex in activated
T cells contains Fra-1 and JunB. Mol. Cell. Biol., 13, 1911–1919.
Cantrell,D. (1996) T cell antigen receptor signal transduction pathways.
Annu. Rev. Immunol., 14, 259–274.
Casolaro,V., Georas,S.N., Song,Z., Zubkoff,I.D., Abdulkadir,S.A.,
Thanos,D. and Ono,S.J. (1995) Inhibition of NF-AT-dependent
transcription by NF-κB: implications for differential gene expression
in T helper cell subsets. Proc. Natl Acad. Sci. USA, 92, 11623–11627.
Cheong,J., Yi,M., Lin,Y. and Murakami,S. (1995) Human RPB5, a
7076
subunit shared by eukaryotic nuclear RNA polymerases, binds human
hepatitis B virus X protein and may play a role in X transactivation.
EMBO J., 14, 143–150.
Chirillo,P., Falco,M., Puri,P.L., Artini,M., Balsano,C., Levrero,M. and
Natoli,G. (1996) Hepatitis B virus pX activates NF-κB dependent
transcription through a Raf-independent pathway. J. Virol., 70, 641–
646.
Chirillo,P., Pagano,S., Natoli,G., Puri,P.L., Burgio,V.L., Balsano,C. and
Levrero,M. (1997) The hepatitis B virus pX gene induces p53-
mediated programmed cell death. Proc. Natl Acad. Sci. USA, 94,
8162–8167.
Chisari,F. and Ferrari,C. (1995) Hepatitis B virus immunopathogenesis.
Annu. Rev. Immunol., 13, 29–60.
Cockeril,P.N., Bert,A.G., Jenkins,F., Ryan,G.R., Shannon,M.F. and
Vadas,M.A. (1995) Human granulocyte-macrophage colony-
stimulating factor enhancer function is associated with cooperative
interactions between AP-1 and NFATp/c. Mol. Cell. Biol., 15,
2071–2079.
Cope,A.P., Liblau,R.S., Yang,X.-D., Congia,M., Laudanna,C.,
Schreiber,R.D., Probert,L., Kollias,G. and McDevitt,H.O. (1997)
Chronic tumor necrosis factor alters T cell responses attenuating T cell
receptor signaling. J. Exp. Med., 185, 1573–1584.
Crabtree,G.R. and Clipstone,N.A. (1994) Signal transmission between
the plasma membrane and the nucleus of T lymphocytes. Annu. Rev.
Biochem., 63, 1045–1083.
Cross,J., Wen,P. and Rutter,W. (1993) Transactivation by hepatitis B
virus X protein is promiscuous and dependent on mitogen-activated
cellular serine/threonine kinases. Proc. Natl Acad. Sci. USA, 90,
8078–8082.
Doria,M., Klein,N., Lucito,R. and Schneider,R.J. (1995) The hepatitis B
virus HBx protein is a dual specificity cytoplasmic activator of Ras
and nuclear activator of transcription factors. EMBO J., 14, 4747–4757.
Durand,D.B., Shaw,J.-P., Bush,M.R., Replogle,R.E., Belagaje,R. and
Crabtree,G.R. (1988) Characterization of antigen receptor response
elements within the IL-2 enhancer. Mol. Cell. Biol., 8, 1715–1724.
Ferrari,C., Pilli,M., Penna,A., Bertoletti,A., Valli,A., Cavalli,A.,
Pasetti,G. and Fiaccadori,F. (1992) Autopresentation of hepatitis B
virus envelope antigens by T cells. J. Virol., 66, 2536–2540.
Franco,A., Paroli,M., Testa,U., Benvenuto,R., Peschle,C., Balsano,F.
and Barnaba,V. (1992) Transferrin receptor mediates up-take and
presentation of hepatitis B envelope antigens by T cells. J. Exp. Med.,
175, 1195–1205.
Fukuda,R., Satoh,S., Nguyen,X.T., Uchida,Y., Kohge,N., Akagi,S.,
Ikeda,S., Watanabe,M. and Fukmoto,S. (1995) Expression rate of
cytokine mRNA in the liver of chronic hepatitis C: comparison with
chronic hepatitis B. J. Gastroenterol., 30, 41–47.
Ganem,D. and Varmus,H.E. (1987) The molecular biology of the hepatitis
B virus. Annu. Rev. Biochem., 56, 651–693.
Ghosh,P., Sica,A., Cippitelli,M., Subleski,J., Lahesmaa,R., Young,H.A.
and Rice,N.R. (1996) Activation of nuclear factor of activated T cells
in a cyclosporin A-resistant pathway. J. Biol. Chem., 271, 7700–7704.
Gonza´lez-Amaro,R. et al. (1994) Induction of tumor necrosis factor-α
production by human hepatocytes in chronic viral hepatitis. J. Exp.
Med., 179, 841–848.
Good,L., Maggirwar,S.B. and Sun,S.-C. (1996) Activation of the IL-2
gene promoter by HTLV-I Tax involves induction of NF-AT complexes
bound to the CD28-responsive element. EMBO J., 15, 3744–3750.
Good,L., Maggirwar,S.B., Harhaj,E.W. and Sun,S.-C. (1997) Constitutive
dephosphorylation and activation of a member of the nuclear factor
of activated T cells, NF-AT1, in Tax-expressing and type I human
T-cell leukemia virus-infected human T cells. J. Biol. Chem., 272,
1425–1428.
Haviv,I., Vaizel,D. and Shaul,Y. (1995) The X protein of hepatis B virus
coactivates potent activation domains. Mol. Cell. Biol., 15, 1079–1085.
Haviv,I., Vaizel,D. and Shaul,Y. (1996) pX, the HBV-encoded coactivator,
interacts with components of the transcription machinery and
stimulates transcription in a TAF-independent manner. EMBO J., 15,
3413–3420.
Haviv,I., Shamay,M., Doitsh,G. and Shaul,Y. (1998) Hepatitis B virus
pX targets TFIIB in transcription coactivation. Mol. Cell. Biol., 18,
1562–1569.
Jain,J., McCaffrey,P.G., Miner,Z., Kerppola,T.K., Lambert,J.N.,
Verdine,G.L., Curran,T. and Rao,A. (1993) The T cell transcription
factor NFATp is a substrate of calcineurin and interacts with Fos and
Jun. Nature, 365, 352–355.
Jain,J., Loh,C. and Rao,A. (1995) Transcriptional regulation of the IL-2
gene. Curr. Opin. Immunol., 7, 333–342.
Activation of NF-AT by HBx
Kekule´,A., Lauer,U., Weiss,L., Luber,B. and Hofsschneider,P. (1993)
Hepatitis B virus transactivator HBx uses a tumour promoter signalling
pathway. Nature, 361, 742–745.
Kieran,M. et al. (1990) The DNA binding subunit of NF-κB is identical
to factor κBF1 and homologous to rel oncogene product. Cell, 62,
1007–1018.
Kinoshita,S., Su,L., Amano,M., Timmerman,L.A., Kaneshima,H. and
Nolan,G.P. (1997) The T cell activation factor NF-ATc positively
regulates HIV-1 replication and gene expression in T cells. Immunity,
6, 235–244.
Klein,N.P. and Schneider,R.J. (1997) Activation of Src family kinases
by hepatitis B virus HBx protein and coupled signaling to Ras. Mol.
Cell. Biol., 17, 6427–6436.
Koike,K. (1995) Hepatitis B virus HBx gene and hepatocarcinogenesis.
Intervirology, 38, 134–142.
Lara-Pezzi,E., Majano,P.L., Go´mez-Gonzalo,M., Garcı´a-Monzo´n,C.,
Moreno-Otero,R., Levrero,M. and Lo´pez-Cabrera,M. (1998) The
hepatitis B virus X protein up-regulates tumor necrosis factor-α gene
expression in hepatocytes. Hepatology, 28, 1013–1021.
Lin,Y., Nomura,T., Cheong,J.H., Dorjsuren,D., Iida,K. and Murakami,S.
(1997) Hepatitis B virus X protein is a transcriptional modulator that
communicates with transcription factor IIB and the RNA polymerase
II subunit 5. J. Biol. Chem., 272, 7132–7139.
Loh,C., Shaw,K.T.-Y., Carew,J., Viola,J.P.B., Luo,C., Perrino,B.A. and
Rao,A. (1996) Calcineurin binds the transcription factor NFAT1 and
reversibly regulates its activity. J. Biol. Chem., 271, 10884–10891.
Luo,C., Burgeon,E. and Rao,A. (1996a) Mechanisms of transactivation
by nuclear factor of activated T cells 1. J. Exp. Med., 184, 141–147.
Luo,C., Shaw,K.T.-Y., Raghavan,A., Aramburu,J., Garcı´a-Cozar,F.,
Perrino,B.A., Hogan,P.G. and Rao,A. (1996b) Interaction of calcineurin
with a domain of the transcription factor NFAT1 that controls nuclear
import. Proc. Natl Acad. Sci. USA, 93, 8907–8912.
Lyakh,L., Ghosh,P. and Rice,N.R. (1997) Expression of NFAT-family
proteins in normal human T cells. Mol. Cell. Biol., 17, 2475–2484.
Maguire,H.F., Hoeffler,J.P. and Siddiqui,A. (1991) HBV X protein alters
the DNA binding specificity of CREB and ATF-2 by protein–protein
interactions. Science, 252, 842–844.
Mahe´,Y., Mukaida,N., Kuno,K., Akiyama,M., Ikeda,N., Matsushima,K.
and Murakami,S. (1991) Hepatitis B virus X protein transactivates
human interleukin-8 gene through acting on nuclear factor κB and
CCAAT/enhancer-binding protein-like cis-element. J. Biol. Chem.,
266, 13759–13763.
Martı´nez-Martı´nez,S., Arco,P.G.D., Armesilla,A.L., Aramburu,J.,
Luo,C., Rao,A. and Redondo,J.M. (1997) Blockade of T-cell activation
by dithiocarbamates involves novel mechanisms of inhibition of
nuclear factor of activated T cells. Mol. Cell. Biol., 17, 6437–6447.
Minden,A., Lin,A., Claret,F.-X., Abo,A. and Karin,M. (1995) Selective
activation of the JNK signalling cascade and c-jun transcriptional
activity by the small GTPases Rac and cdc42Hs. Cell, 81, 1147–1157.
Murakami,S., Cheong,J., Ohno,S., Matsushima,K. and Kaneko,S. (1994)
Transactivation of human hepatitis B virus X protein, HBx, operates
through a mechanism distinct from protein kinase C and okadaic acid
activation pathways. Virology, 199, 243–246.
Natoli,G., Avantaggiati,M., Chirillo,P., Constanzo,A., Artini,M.,
Balsano,C. and Levrero,M. (1994a) Induction of the DNA-binding
activity of c-Jun/c-Fos heterodimers by the hepatitis B virus
transactivator pX. Mol. Cell. Biol., 14, 989–998.
Natoli,G., Avantaggiati,M., Chirillo,P., Puri,P., Ianni,A., Balsano,C. and
Levrero,M. (1994b) Ras- and Raf-dependent activation of c-jun
transcriptional activity by hepatitis B virus transactivator pX.
Oncogene, 9, 2836–2843.
Northrop,J.P., Ullman,K.S. and Crabtree,G.R. (1993) Characterization of
the nuclear and cytoplasmic components of the lymphoid-specific
nuclear factor of activated T cells. J. Biol. Chem., 268, 2917–2923.
Northrop,J.P., Ho,S.N., Chen,L., Thomas,D.J., Timmerman,L.A.,
Nolan,G.P., Admon,A. and Crabtree,G.R. (1994) NF-AT components
define a family of transcription factors targeted in T-cell activation.
Nature, 369, 497–502.
Okamoto,S.-I., Mukaida,N., Yasumoto,K., Rice,N., Ishikawa,Y.,
Horiguchi,H., Murakami,S. and Matsushima,K. (1994) The
interleukin-8 AP-1 and κB-like sites are genetic end targets of FK506-
sensitive pathway accompained by calcium mobilization. J. Biol.
Chem., 269, 8582–8589.
Qadri,I., Maguire,H. and Siddiqui,A. (1995) Hepatitis B virus
transactivator protein X interacts with the TATA-binding protein. Proc.
Natl Acad. Sci. USA, 92, 1003–1007.
7077
Rao,A. (1994) NFATp: a transcription factor required for the coordinated
induction of several cytokine genes. Immunol. Today, 15, 274–281.
Rao,A., Luo,C. and Hogan,P.G. (1997) Transcription factors of the NFAT
family: regulation and function. Annu. Rev. Immunol., 15, 707–747.
Rooney,J.W., Hodge,M.R., McCaffrey,P.G., Rao,A. and Glimcher,L.H.
(1994) A common factor regulates both Th1- and Th2-specific cytokine
gene expression. EMBO J., 13, 625–633.
Rooney,J.W., Hoey,T. and Glimcher,L.H. (1995) Coordinate and
cooperative roles for NF-AT and AP-1 in the regulation of the murine
IL-4 gene. Immunity, 2, 473–483.
Schreiber,S.L. and Crabtree,G.R. (1992) The mechanism of action of
cyclosporin A and FK506. Immunol. Today, 13, 136–142.
Schreiber,E., Matthias,P., Muller,M.M. and Schaffner,W. (1989) Rapid
detection of octamer binding proteins with ‘mini-extracts’, prepared
from a small number of cells. Nucleic Acids Res., 17, 6419.
Shaw,K.T.-Y., Ho,A.M., Raghavan,A., Kim,J., Jain,J., Park,J., Sharma,S.
and Rao,A. (1995) Immunosuppressive drugs prevent a rapid
dephosphorylation of the transcription factor NFAT1 in stimulated
immune cells. Proc. Natl Acad. Sci. USA, 92, 11205–11209.
Shindo,M., Mullin,G.E., Braun-Elwert,L., Bergasa,N.V., Jones,E.A. and
James,S.P. (1996) Cytokine mRNA expression in the liver of patients
with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB).
Clin. Exp. Immunol., 105, 254–259.
Sigal,N.H. and Dumont,F.J. (1992) Cyclosporin A, FK-506 and
rapamycin: pharmacologic probes of lymphocyte signal transduction.
Annu. Rev. Immunol., 10, 519–560.
Su,F. and Schneider,R.J. (1996) Hepatitis B virus HBx protein activates
transcription factor NF-κB by acting on multiple cytoplasmic inhibitors
of rel-related proteins. J. Virol., 70, 4558–4566.
Tiollais,P., Pourcel,C. and Dejean,A. (1985) The hepatitis B virus.
Nature, 317, 489–495.
Trede,N.S., Tsytsykova,A.V., Chatila,T., Goldfeld,A.E. and Geha,R.S.
(1995) Transcriptional activation of the human TNF-α promoter by
superantigen in human monocytic cells. J. Immunol., 155, 902–908.
Tsai,E.Y., Yie,J., Thanos,D. and Goldfeld,A.E. (1996) Cell-type-specific
regulation of the human tumor necrosis factor-alpha gene in B cells
and T cells by NFATp and ATF-2/Jun. Mol. Cell. Biol., 16, 5232–5244.
Vassalli,P. (1992) The pathophysiology of tumor necrosis factor. Annu.
Rev. Immunol., 10, 411–452.
Yao,J., Mackman,N., Edgington,T.S. and Fan,S.-T. (1997) Lipo-
polysaccharide induction of the tumor necrosis factor-α promoter in
human monocytic cells. J. Biol. Chem., 272, 17795–17801.
Yen,T.S.B. (1996) Hepadnaviral X protein: review of recent progress.
J. Biomed. Sci., 3, 20–30.
Yoo,Y.D., Ueda,H., Park,K., Flanders,K.C., Lee,Y.I., Jay,G. and Kim,S.J.
(1996) Regulation of transforming growth factor-β1 expression by the
hepatitis B virus (HBV) X transactivator. J. Clin. Invest., 97, 388–395.
Received February 23, 1998; revised September 11, 1998;
accepted October 2, 1998
